Steven Cohen's IMVT Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 2 M shares of Immunovant, Inc. (IMVT) worth $50.84 M, representing 0.06% of the portfolio. First purchased in 2020-Q1, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in IMVT, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 2.67 M shares. Largest reduction occurred in Q4 2022, reducing 1.53 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Immunovant (IMVT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Immunovant (IMVT) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -1.44 M | Reduce 41.90% | 2 M | $25.42 |
| Q3 2025 | +105,828 | Add 3.17% | 3.44 M | $16.12 |
| Q2 2025 | +2.53 M | Add 316.03% | 3.34 M | $16.00 |
| Q1 2025 | +801,927 | New Buy | 801,927 | $17.09 |
| Q2 2024 | -1.38 M | Sold Out | 0 | $0.00 |
| Q1 2024 | -1.28 M | Reduce 48.11% | 1.38 M | $32.31 |
| Q4 2023 | +2.67 M | New Buy | 2.67 M | $42.13 |
| Q3 2023 | -457,467 | Sold Out | 0 | $0.00 |
| Q2 2023 | +457,467 | New Buy | 457,467 | $18.97 |
| Q1 2023 | -435,751 | Sold Out | 0 | $0.00 |
| Q4 2022 | -1.53 M | Reduce 77.85% | 435,751 | $17.75 |
| Q3 2022 | +1.97 M | New Buy | 1.97 M | $5.58 |
| Q2 2022 | -459,300 | Sold Out | 0 | $0.00 |
| Q1 2022 | -441,200 | Reduce 49.00% | 459,300 | $5.51 |
| Q4 2021 | +900,500 | New Buy | 900,500 | $8.52 |
| Q2 2021 | -187,900 | Sold Out | 0 | $0.00 |
| Q1 2021 | -70,500 | Reduce 27.28% | 187,900 | $16.04 |
| Q4 2020 | -1.25 M | Reduce 82.92% | 258,400 | $46.19 |
| Q3 2020 | +1.36 M | Add 911.25% | 1.51 M | $35.19 |
| Q2 2020 | +126,251 | Add 539.72% | 149,643 | $24.35 |
| Q1 2020 | +23,392 | New Buy | 23,392 | $15.56 |
Steven Cohen's Immunovant Investment FAQs
Steven Cohen first purchased Immunovant, Inc. (IMVT) in Q1 2020, acquiring 23,392 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Immunovant, Inc. (IMVT) for 21 quarters since Q1 2020.
Steven Cohen's largest addition to Immunovant, Inc. (IMVT) was in Q4 2023, adding 2,666,883 shares worth $112.36 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 2,000,000 shares of Immunovant, Inc. (IMVT), valued at approximately $50.84 M.
As of the Q4 2025 filing, Immunovant, Inc. (IMVT) represents approximately 0.06% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Immunovant, Inc. (IMVT) was 3,442,078 shares, as reported at the end of Q3 2025.